IM Cannabis files resale registration for 17.3 million shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: PRnewswire
IM Cannabis Corp. has seen a significant price increase of 166.09% in pre-market trading, crossing above its 20-day SMA.
The company has filed a resale registration statement with the SEC for 17,276,931 common shares, indicating its active engagement in capital markets. This includes shares linked to convertible promissory notes, suggesting a strategy to optimize its capital structure. While IM Cannabis will not receive proceeds from the sale, this move may enhance liquidity for shareholders and increase market interest in the stock.
This registration statement, pending SEC approval, could influence market confidence and future financing capabilities, potentially impacting the stock's price performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Corp. to Sell European Assets to Streamline Operations
- Transaction Overview: IM Cannabis Corp. has entered into a letter of intent with Slil.com Holding Ltd. to sell its European assets, including IMC Holdings, which is expected to reduce approximately C$10.5 million in debt, thereby improving the company's financial position and cash flow.
- Core Business Retention: Following the transaction, IMC will retain its core Israeli operations, focusing on enhancing market competitiveness through subsidiaries like Focus Medical Herbs while pursuing new investment opportunities to bolster long-term shareholder value.
- Board Review: The IMC board has established a special committee to evaluate the fairness of the transaction and has commissioned Beta Finance T.Y.S Ltd. for an independent assessment to ensure the deal aligns with shareholder interests.
- Related Party Transaction: This transaction is classified as a related party transaction due to Slil being controlled by IMC's CEO Oren Shuster, necessitating compliance with MI 61-101 regulations to secure minority shareholder approval.
See More
IM Cannabis Corp. to Sell European Assets to Streamline Operations
- Transaction Overview: IM Cannabis Corp. has signed a letter of intent with Slil.com Holding Ltd. to sell its European assets, including Adjupharm GmbH in Germany, which is expected to reduce approximately C$10.5 million in debt, thereby improving the company's financial position.
- Debt Relief: Slil will assume C$10.5 million in liabilities from IMC Holdings, comprising C$7.5 million in retained liabilities and C$3 million in short-term liabilities, significantly alleviating IMC's financial burden and enhancing its working capital.
- Focus on Israeli Market: Following the transaction, IMC will retain its core operations in Israel, concentrating on increasing market share through its subsidiaries while pursuing new investment opportunities to optimize resource allocation.
- Independent Evaluation Mechanism: The IMC board has established a special committee to assess the fairness of the transaction and has engaged Beta Finance T.Y.S Ltd. for an independent report to ensure the deal aligns with shareholder interests.
See More
IM Cannabis Files Resale Registration Statement for 17.3 Million Shares
- Resale Registration Statement Filed: IM Cannabis Corp. has filed a resale registration statement with the SEC for a total of 17,276,931 common shares, indicating the company's active engagement in capital markets and financing capabilities.
- Convertible Note Details: The registration includes 4,000,000, 6,720,000, and 4,375,000 common shares corresponding to convertible promissory notes dated April, May, and June 2026, respectively, suggesting the company is optimizing its capital structure through debt instruments.
- Shareholder Sale Plan: While the company will not receive proceeds from the sale of shares by shareholders, this move provides liquidity for shareholders, potentially increasing market interest in the company's stock and impacting its price performance.
- Market Compliance: The registration statement has not yet become effective, indicating that the company must still meet SEC review requirements, which may affect its future financing capabilities and market confidence.
See More
IM Cannabis Files Resale Registration Statement for 17.3 Million Shares
- Registration Statement Filed: IM Cannabis Corp. has filed a resale registration statement with the SEC for a total of 17,276,931 common shares, indicating the company's active engagement in capital markets.
- Convertible Note Details: The registration includes 4,000,000, 6,720,000, and 4,375,000 common shares linked to three convertible notes, demonstrating the company's use of debt instruments for capital operations.
- Shareholder Sale Opportunity: Once the registration statement is approved, selling shareholders may use the associated prospectus to resell the registered securities, potentially impacting market liquidity and stock price volatility.
- No Expected Proceeds: IM Cannabis will not receive any proceeds from the sale of securities by shareholders, reflecting a cautious approach to managing its capital structure.
See More
IM Cannabis Closes $225,000 Convertible Note Financing
- Financing Amount: IM Cannabis Corp. successfully closed a $225,000 convertible note financing with an institutional investor, demonstrating the company's ability to attract capital in the market.
- Interest Rate and Terms: The note carries an 8% annual interest rate, increasing to 14% upon default, indicating potential risks in financing costs while reflecting investor caution regarding the company's creditworthiness.
- Conversion Price Mechanism: The conversion price is set at $0.288 per share or 90% of the lowest daily volume-weighted average price over the preceding 20 trading days, providing investors with flexible return options that may impact future equity structure.
- Future Plans: IM Cannabis intends to use the proceeds for general corporate purposes and has committed to filing a resale registration statement in the coming months, highlighting the company's focus on compliance and transparency to enhance investor confidence.
See More
IM Cannabis Closes $225,000 Convertible Note Financing
- Financing Size: IM Cannabis successfully closed a $225,000 convertible note financing with an institutional investor, reflecting market confidence in its capital structure and enhancing the company's financial flexibility.
- Note Terms: The issued convertible note has a principal amount of $225,000 with a 10% original issuance discount and an annual interest rate of 8%, which increases to 14% in the event of default, providing the company with a relatively low-cost financing option.
- Share Conversion Mechanism: IM Cannabis stated that the note cannot be repaid in cash and will only be settled through the issuance of common shares upon conversion, which will help alleviate cash flow pressure but may dilute existing shareholders' equity.
- Use of Proceeds: The company intends to use the net proceeds for general corporate purposes, indicating a commitment to continue investing in its core business for long-term growth, although this may pose short-term risks of shareholder dilution.
See More
IM Cannabis Corp. to Sell European Assets to Streamline Operations
- Transaction Overview: IM Cannabis Corp. has entered into a letter of intent with Slil.com Holding Ltd. to sell its European assets, including IMC Holdings, which is expected to reduce approximately C$10.5 million in debt, thereby improving the company's financial position and cash flow.
- Core Business Retention: Following the transaction, IMC will retain its core Israeli operations, focusing on enhancing market competitiveness through subsidiaries like Focus Medical Herbs while pursuing new investment opportunities to bolster long-term shareholder value.
- Board Review: The IMC board has established a special committee to evaluate the fairness of the transaction and has commissioned Beta Finance T.Y.S Ltd. for an independent assessment to ensure the deal aligns with shareholder interests.
- Related Party Transaction: This transaction is classified as a related party transaction due to Slil being controlled by IMC's CEO Oren Shuster, necessitating compliance with MI 61-101 regulations to secure minority shareholder approval.
See More
IM Cannabis Corp. to Sell European Assets to Streamline Operations
- Transaction Overview: IM Cannabis Corp. has signed a letter of intent with Slil.com Holding Ltd. to sell its European assets, including Adjupharm GmbH in Germany, which is expected to reduce approximately C$10.5 million in debt, thereby improving the company's financial position.
- Debt Relief: Slil will assume C$10.5 million in liabilities from IMC Holdings, comprising C$7.5 million in retained liabilities and C$3 million in short-term liabilities, significantly alleviating IMC's financial burden and enhancing its working capital.
- Focus on Israeli Market: Following the transaction, IMC will retain its core operations in Israel, concentrating on increasing market share through its subsidiaries while pursuing new investment opportunities to optimize resource allocation.
- Independent Evaluation Mechanism: The IMC board has established a special committee to assess the fairness of the transaction and has engaged Beta Finance T.Y.S Ltd. for an independent report to ensure the deal aligns with shareholder interests.
See More
IM Cannabis Files Resale Registration Statement for 17.3 Million Shares
- Resale Registration Statement Filed: IM Cannabis Corp. has filed a resale registration statement with the SEC for a total of 17,276,931 common shares, indicating the company's active engagement in capital markets and financing capabilities.
- Convertible Note Details: The registration includes 4,000,000, 6,720,000, and 4,375,000 common shares corresponding to convertible promissory notes dated April, May, and June 2026, respectively, suggesting the company is optimizing its capital structure through debt instruments.
- Shareholder Sale Plan: While the company will not receive proceeds from the sale of shares by shareholders, this move provides liquidity for shareholders, potentially increasing market interest in the company's stock and impacting its price performance.
- Market Compliance: The registration statement has not yet become effective, indicating that the company must still meet SEC review requirements, which may affect its future financing capabilities and market confidence.
See More
IM Cannabis Files Resale Registration Statement for 17.3 Million Shares
- Registration Statement Filed: IM Cannabis Corp. has filed a resale registration statement with the SEC for a total of 17,276,931 common shares, indicating the company's active engagement in capital markets.
- Convertible Note Details: The registration includes 4,000,000, 6,720,000, and 4,375,000 common shares linked to three convertible notes, demonstrating the company's use of debt instruments for capital operations.
- Shareholder Sale Opportunity: Once the registration statement is approved, selling shareholders may use the associated prospectus to resell the registered securities, potentially impacting market liquidity and stock price volatility.
- No Expected Proceeds: IM Cannabis will not receive any proceeds from the sale of securities by shareholders, reflecting a cautious approach to managing its capital structure.
See More
IM Cannabis Closes $225,000 Convertible Note Financing
- Financing Amount: IM Cannabis Corp. successfully closed a $225,000 convertible note financing with an institutional investor, demonstrating the company's ability to attract capital in the market.
- Interest Rate and Terms: The note carries an 8% annual interest rate, increasing to 14% upon default, indicating potential risks in financing costs while reflecting investor caution regarding the company's creditworthiness.
- Conversion Price Mechanism: The conversion price is set at $0.288 per share or 90% of the lowest daily volume-weighted average price over the preceding 20 trading days, providing investors with flexible return options that may impact future equity structure.
- Future Plans: IM Cannabis intends to use the proceeds for general corporate purposes and has committed to filing a resale registration statement in the coming months, highlighting the company's focus on compliance and transparency to enhance investor confidence.
See More
IM Cannabis Closes $225,000 Convertible Note Financing
- Financing Size: IM Cannabis successfully closed a $225,000 convertible note financing with an institutional investor, reflecting market confidence in its capital structure and enhancing the company's financial flexibility.
- Note Terms: The issued convertible note has a principal amount of $225,000 with a 10% original issuance discount and an annual interest rate of 8%, which increases to 14% in the event of default, providing the company with a relatively low-cost financing option.
- Share Conversion Mechanism: IM Cannabis stated that the note cannot be repaid in cash and will only be settled through the issuance of common shares upon conversion, which will help alleviate cash flow pressure but may dilute existing shareholders' equity.
- Use of Proceeds: The company intends to use the net proceeds for general corporate purposes, indicating a commitment to continue investing in its core business for long-term growth, although this may pose short-term risks of shareholder dilution.
See More
